American Tungsten Reprices Non-Brokered LIFE Private Placement to $2.58 per Share
aTyr PharmaaTyr Pharma(US:LIFE) Newsfile·2025-10-20 21:10

Core Viewpoint - American Tungsten Corp. has revised the terms of its non-brokered private placement under the Listed Issuer Financing Exemption, adjusting the share price to $2.58 while maintaining the offering size at $20 million with no warrants [1][2]. Group 1: Offering Details - The updated price for the LIFE Offering is set at $2.58 per common share, with the offering remaining upsized to $20 million and finders' fees capped at 6.0% in cash [2]. - An amended and restated LIFE offering document will be filed on www.sedarplus.ca and the company's website, encouraging prospective investors to review it before making investment decisions [3]. Group 2: Management Commentary - CEO Ali Haji stated that the repricing aligns the financing with current market dynamics and reflects the company's commitment to shareholders while maintaining capital discipline and long-term value creation [4]. - The company aims to advance toward production and become a significant tungsten producer in the United States, addressing critical metal scarcity [4]. Group 3: Use of Proceeds - The net proceeds from the offering will be directed towards the upcoming exploration program at the IMA Mine, fast-tracking technical studies, and providing additional working capital [5]. Group 4: Company Overview - American Tungsten Corp. is focused on high-potential tungsten and magnetite assets in North America, particularly advancing the Ima Mine Project in Idaho to commercial production [6]. - The Ima Mine Project is a historic underground tungsten property with significant infrastructure, and the company holds an exclusive option to acquire full ownership, subject to a 2% royalty [6].